CF drugs will edge Vertex ahead of GSK in $46.6 billion respiratory market by 2022, report says

18 August 2016

The market for respiratory drugs will grow from its 2015 size of $28.1 billion to $46.6 billion by 2022 at a compound annual growth rate (CAGR) of 7.5%, according to business intelligence provider GBI Research.

This market – covering asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and cystic fibrosis, will see patent expirations of a number of big-selling products, allowing for the sale of generics, though this will be offset by new treatment launches, the report predicts.

The expiring patents referred to include two for UK pharma major GlaxoSmithKline (LSE: GSK), namely Advair (fluticasone/salmeterol) and Ventolin (salbutamol).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK